TN2010000122A1 - Compounds and compositions as modulators of gpr119 activity - Google Patents

Compounds and compositions as modulators of gpr119 activity

Info

Publication number
TN2010000122A1
TN2010000122A1 TNP2010000122A TN2010000122A TN2010000122A1 TN 2010000122 A1 TN2010000122 A1 TN 2010000122A1 TN P2010000122 A TNP2010000122 A TN P2010000122A TN 2010000122 A TN2010000122 A TN 2010000122A TN 2010000122 A1 TN2010000122 A1 TN 2010000122A1
Authority
TN
Tunisia
Prior art keywords
compounds
compositions
modulators
gpr119 activity
gpr119
Prior art date
Application number
TNP2010000122A
Other languages
English (en)
Inventor
Philip Alper
Mihai Azimioara
Christopher Cow
Robert Epple
Songchun Jiang
Gerald Lelais
Pierre Yves Michellys
Daniel Mutnick
Victor Nikulin
Baker Lucas Westcott
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Publication of TN2010000122A1 publication Critical patent/TN2010000122A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TNP2010000122A 2007-09-20 2010-03-19 Compounds and compositions as modulators of gpr119 activity TN2010000122A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97406407P 2007-09-20 2007-09-20
US4526308P 2008-04-15 2008-04-15
PCT/US2008/075145 WO2009038974A1 (fr) 2007-09-20 2008-09-03 Composés et compositions en tant que modulateurs de l'activité de gpr119

Publications (1)

Publication Number Publication Date
TN2010000122A1 true TN2010000122A1 (en) 2011-09-26

Family

ID=40039643

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2010000122A TN2010000122A1 (en) 2007-09-20 2010-03-19 Compounds and compositions as modulators of gpr119 activity

Country Status (22)

Country Link
US (3) US8153635B2 (fr)
EP (1) EP2197873B1 (fr)
JP (1) JP5465177B2 (fr)
KR (1) KR20100055536A (fr)
CN (1) CN101801954B (fr)
AR (1) AR068496A1 (fr)
AU (1) AU2008302570B2 (fr)
BR (1) BRPI0817211A2 (fr)
CA (1) CA2697551C (fr)
CL (1) CL2008002787A1 (fr)
CO (1) CO6270362A2 (fr)
CR (1) CR11292A (fr)
EC (1) ECSP10010042A (fr)
ES (1) ES2499018T3 (fr)
MA (1) MA31764B1 (fr)
MX (1) MX2010003117A (fr)
NZ (1) NZ583495A (fr)
PE (1) PE20090708A1 (fr)
RU (1) RU2443699C2 (fr)
TN (1) TN2010000122A1 (fr)
TW (1) TWI368618B (fr)
WO (1) WO2009038974A1 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
RU2443699C2 (ru) 2007-09-20 2012-02-27 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
EP2108960A1 (fr) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
US20110263557A1 (en) * 2008-04-07 2011-10-27 Irm Llc Compounds and compositions as modulators of gpr119 activity
EP2331503B1 (fr) * 2008-07-11 2013-08-21 Irm Llc 4-phénoxyméthylpipéridines comme modulateurs de l activité de gpr119
UA104188C2 (en) * 2009-06-18 2014-01-10 Кадила Хелткере Лимитед Gpr 119 agonists
WO2010149684A1 (fr) 2009-06-24 2010-12-29 Boehringer Ingelheim International Gmbh Nouveaux composés, composition pharmaceutique et procédés correspondants
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
AR077638A1 (es) * 2009-07-15 2011-09-14 Lilly Co Eli Compuesto de (metanosulfonil -piperidin )-( alcoxi-aril) -tetrahidro- piridina , composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para el tratamiento de diabetes u obesidad
US8552022B2 (en) 2009-08-13 2013-10-08 Merck Sharp & Dohme Corp. Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
WO2011030139A1 (fr) 2009-09-11 2011-03-17 Astrazeneca Ab Derives de 4-(pyrimidin-2-yl)-piperazine et de 4-(pyrimidin-2-yl)-piperidine utilises en tant que modulateurs du gpr119
US8575168B2 (en) * 2009-10-09 2013-11-05 Irm Llc Compounds and compositions as modulators of GPR119 activity
US8912206B2 (en) 2009-11-23 2014-12-16 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
JP5856980B2 (ja) 2010-01-27 2016-02-10 アリーナ ファーマシューティカルズ， インコーポレイテッド （Ｒ）−２−（７−（４−シクロペンチル−３−（トリフルオロメチル）ベンジルオキシ）−１，２，３，４−テトラヒドロシクロペンタ［ｂ］インドール−３−イル）酢酸およびその塩の調製のためのプロセス
CA2789622C (fr) * 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles utilises en tant qu'inhibiteurs du facteur xia
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
KR101871011B1 (ko) 2010-09-22 2018-06-25 아레나 파마슈티칼스, 인크. Ｇｐｒ１１９ 수용체의 조절제 및 그와 관련된 장애의 치료
UY33805A (es) * 2010-12-17 2012-07-31 Boehringer Ingelheim Int ?Derivados de dihidrobenzofuranil-piperidinilo, aza-dihidrobenzofuranilpiperidinilo y diaza-dihidrobenzofuranil-piperidinilo, composiciones farmacéuticas que los contienen y usos de los mismos?.
WO2012135570A1 (fr) * 2011-04-01 2012-10-04 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés
JP6047144B2 (ja) * 2011-04-08 2016-12-21 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 置換シクロプロピル化合物、このような化合物を含有する組成物および処置方法
WO2012145361A1 (fr) * 2011-04-19 2012-10-26 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci
JP2014517036A (ja) 2011-06-16 2014-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 置換シクロプロピル化合物、そのような化合物を含有する組成物および治療方法
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
WO2013048916A1 (fr) * 2011-09-30 2013-04-04 Merck Sharp & Dohme Corp. Composés de cyclopropyle substitués, compositions contenant ces composés et méthodes de traitement
WO2013062838A1 (fr) 2011-10-24 2013-05-02 Merck Sharp & Dohme Corp. Composés de pipéridinyle substitués utilisés comme agonistes du récepteur gpr119
JP6101279B2 (ja) 2011-11-15 2017-03-22 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｇｐｒ１１９アゴニストとして有用な置換シクロプロピル化合物
WO2013122821A1 (fr) * 2012-02-14 2013-08-22 Merck Sharp & Dohme Corp. Composés cyclopropylés substitués utiles comme agonistes de gpr119
CN104364246B (zh) 2012-06-12 2018-05-22 株式会社钟根堂 用作gpr119激动剂的哌啶衍生物
EP2872127A1 (fr) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique
WO2014052619A1 (fr) * 2012-09-27 2014-04-03 Irm Llc Dérivés et compositions de pipéridine comme modulateurs de l'activité de gpr119
ES2731823T3 (es) 2013-11-26 2019-11-19 Chong Kun Dang Pharmaceutical Corp Derivados de amida para el agonista del GPR119
CN111018790B (zh) 2014-04-29 2023-09-19 Fmc公司 哒嗪酮除草剂
KR101726819B1 (ko) 2014-10-27 2017-04-13 동아에스티 주식회사 Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
UA126268C2 (uk) 2015-01-06 2022-09-14 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СТАНІВ, ПОВ'ЯЗАНИХ З РЕЦЕПТОРОМ S1P<sub>1 </sub>
US10758525B2 (en) 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
CN104610390A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一种含氨基葡萄糖和腈基吡啶结构的gpr119激动剂及其用途
CN104610393A (zh) * 2015-02-13 2015-05-13 佛山市赛维斯医药科技有限公司 一类含氨基葡萄糖和卤代吡啶结构化合物及其用途
EA201890096A1 (ru) 2015-06-22 2018-08-31 Арена Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКАЯ L-АРГИНИНОВАЯ СОЛЬ (R)-2-(7-(4-ЦИКЛОПЕНТИЛ-3-(ТРИФТОРМЕТИЛ)БЕНЗИЛОКСИ)-1,2,3,4-ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛ-3-ИЛ)УКСУСНОЙ КИСЛОТЫ (СОЕДИНЕНИЯ 1) ДЛЯ ПРИМЕНЕНИЯ ПРИ РАССТРОЙСТВАХ, СВЯЗАННЫХ С S1P-РЕЦЕПТОРОМ
RU2764746C2 (ru) 2015-10-28 2022-01-20 Фмк Корпорейшн Новые пиридазиноновые гербициды
CN112250670B (zh) 2016-06-07 2021-06-08 北京加科思新药研发有限公司 可用作shp2抑制剂的新型杂环衍生物
EP3529245A4 (fr) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. Composés et utilisations de ces derniers
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
TWI785022B (zh) 2017-03-28 2022-12-01 美商富曼西公司 新穎噠嗪酮類除草劑
WO2019018795A1 (fr) * 2017-07-20 2019-01-24 Yumanity Therapeutics Composés et utilisations de ces composés
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
WO2019209962A1 (fr) 2018-04-25 2019-10-31 Yumanity Therapeutics, Inc. Composés et leurs utilisations
BR112022006546A2 (pt) 2019-10-07 2022-08-30 Kallyope Inc Agonistas de gpr119
CN111303120A (zh) * 2020-03-14 2020-06-19 江巨东 一种盐酸法舒地尔的制备方法
WO2022216709A1 (fr) * 2021-04-06 2022-10-13 Kallyope, Inc. Agonistes de gpr119

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2341925A1 (de) 1973-08-20 1975-03-06 Thomae Gmbh Dr K Neue pyrimidinderivate und verfahren zu ihrer herstellung
AT340933B (de) 1973-08-20 1978-01-10 Thomae Gmbh Dr K Verfahren zur herstellung neuer pyrimidinderivate und ihrer saureadditionssalze
JPS5612114B2 (fr) 1974-06-07 1981-03-18
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US4450171A (en) 1980-08-05 1984-05-22 Merck & Co., Inc. Antihypercholesterolemic compounds
US4448784A (en) 1982-04-12 1984-05-15 Hoechst-Roussel Pharmaceuticals, Inc. 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof
US4499289A (en) 1982-12-03 1985-02-12 G. D. Searle & Co. Octahydronapthalenes
CA1327360C (fr) 1983-11-14 1994-03-01 William F. Hoffman Analogues oxo d'agents antihypercholesterolemiants ayant les caracteristiques de la mevinoline
US4613610A (en) 1984-06-22 1986-09-23 Sandoz Pharmaceuticals Corp. Cholesterol biosynthesis inhibiting pyrazole analogs of mevalonolactone and its derivatives
US4686237A (en) 1984-07-24 1987-08-11 Sandoz Pharmaceuticals Corp. Erythro-(E)-7-[3'-C1-3 alkyl-1'-(3",5"-dimethylphenyl)naphth-2'-yl]-3,5-dihydroxyhept-6-enoic acids and derivatives thereof
US4647576A (en) 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
ATE60571T1 (de) 1984-12-04 1991-02-15 Sandoz Ag Inden-analoga von mevalonolakton und ihre derivate.
US4668794A (en) 1985-05-22 1987-05-26 Sandoz Pharm. Corp. Intermediate imidazole acrolein analogs
EP0221025A1 (fr) 1985-10-25 1987-05-06 Sandoz Ag Analogues hétérocycliques de la mévalonolactone et dérivés de ceux-ci, leur procédé de préparation et leur application comme médicaments
FR2596393B1 (fr) 1986-04-01 1988-06-03 Sanofi Sa Derives de l'acide hydroxy-3 dihydroxyoxophosphorio-4 butanoique, leur procede de preparation, leur application comme medicament et les compositions les renfermant
DK277488A (da) 1987-05-22 1988-11-23 Squibb & Sons Inc Phosporholdige hmg-coa-reduktaseinhibitorer, deres anvendelse og fremstilling samt mellemprodukter ved fremstillingen
US5506219A (en) 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
US5753675A (en) 1989-03-03 1998-05-19 Novartis Pharmaceuticals Corporation Quinoline analogs of mevalonolactone and derivatives thereof
US5776983A (en) 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5491134A (en) 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
DE69636677D1 (de) 1995-12-13 2006-12-14 Univ California Kristalle der mit einem Ligand komplexierten Ligandenbindedomäne des Schilddrüsenhormonrezeptors
US5770615A (en) 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
GB9713739D0 (en) 1997-06-27 1997-09-03 Karobio Ab Thyroid receptor ligands
AU767456B2 (en) 1998-07-06 2003-11-13 Bristol-Myers Squibb Company Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
JP2003534767A (ja) 1998-11-20 2003-11-25 アリーナ・フアーマシユーチカルズ・インコーポレーテツド ヒトオーファンｇタンパク質共役型受容体
US20070087363A1 (en) 1998-12-22 2007-04-19 Myriad Genetics, Incorporated Therapeutic methods, compounds and compositions
GB9828442D0 (en) 1998-12-24 1999-02-17 Karobio Ab Novel thyroid receptor ligands and method II
US6221660B1 (en) 1999-02-22 2001-04-24 Synaptic Pharmaceutical Corporation DNA encoding SNORF25 receptor
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
EP1939188A1 (fr) 1999-09-22 2008-07-02 Bristol-Myers Squibb Company Dérivés d'oxa et thiazole utiles en tant qu'agents antidiabétiques et anti-obésité
JP2003513629A (ja) 1999-11-03 2003-04-15 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 新規なｇｐｃｒ＿ｋｄ５ポリペプチドおよびそのｄｎａ配列
US20030082534A1 (en) 1999-11-16 2003-05-01 Peter Lind Novel G protein-coupled receptors
EP2172560A3 (fr) 2000-02-24 2010-09-29 Xenon Pharmaceuticals Inc. Méthodes et compositions utilisant la stéaoryl-CoA desaturase pour identifier des agents thérapeutiques reduisant les trigycerides
DK1287133T3 (da) 2000-05-18 2007-03-26 Bayer Healthcare Ag Regulering af human dopamin-lignende G-protein-koblet receptor
GB0013383D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Therapeutic benzamide derivatives
ATE374765T1 (de) 2000-07-27 2007-10-15 Lilly Co Eli Substituierte heterocyclische amide
US20040067499A1 (en) 2000-08-04 2004-04-08 Tatsuya Haga Novel g protein-coupled receptor
JP2002112793A (ja) 2000-08-04 2002-04-16 Japan Science & Technology Corp 新規ｇ蛋白質共役受容体
US6653102B2 (en) 2000-10-17 2003-11-25 Myriad Genetics, Inc. Nucleic acid encoding a phosphatase 2C that interacts with Fe 65
RU2004100839A (ru) 2001-07-02 2005-06-20 Астразенека Аб (Se) Производные пиперидина полезные в качестве модуляторов активности рецепторов хемокинов
TW200303742A (en) 2001-11-21 2003-09-16 Novartis Ag Organic compounds
ATE521592T1 (de) 2002-03-13 2011-09-15 Janssen Pharmaceutica Nv Histone-deacetylase-inhibitoren
CA2483314A1 (fr) 2002-04-25 2003-11-06 Pharmacia Corporation Acides piperidinylsulfonylmethylhydroxamiques et piperazinylsulfonylmethylhydroxamiques et leur utilisation comme inhibiteurs de protease
US20040007251A1 (en) 2002-07-10 2004-01-15 Kimberly-Clark Worldwide, Inc. Cleaners for the control and removal of allergens
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
GB0224084D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
US20030143590A1 (en) 2002-11-18 2003-07-31 Shyam Ramakrishnan Regulation of human dopamine-like g protein- coupled receptor
WO2004047755A2 (fr) 2002-11-22 2004-06-10 Japan Tobacco Inc. Heterocycles contenant de l'azote bicyclique fusionne
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
US8293751B2 (en) 2003-01-14 2012-10-23 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
EP1606282B1 (fr) 2003-02-24 2008-11-12 Arena Pharmaceuticals, Inc. Derives d'aryle et heteroaryle susbtitues tenant lieu de modulateurs du metabolisme du glucose et prophylaxie et traitement de troubles associes
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
AU2004257267B2 (en) 2003-07-14 2009-12-03 Arena Pharmaceuticals,Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
TWI345974B (en) 2003-07-30 2011-08-01 Xenon Pharmaceuticals Inc Pyridazine derivatives and their use in the inhibition of stearoyl-coa desaturase
ES2377406T3 (es) 2003-07-30 2012-03-27 Xenon Pharmaceuticals Inc. Derivados de la piperazina y su uso como agentes terapéuticos
WO2005013907A2 (fr) 2003-08-07 2005-02-17 Japan Tobacco Inc. Derives de pyrrolo[1,2-b]pyridazine
GB0325192D0 (en) 2003-10-29 2003-12-03 Astrazeneca Ab Method of use
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
JP4958560B2 (ja) * 2003-12-24 2012-06-20 プロシディオン・リミテッド Ｇｐｃｒ受容体作動薬としてのヘテロ環誘導体
DK1756084T3 (da) 2004-06-04 2009-03-23 Arena Pharm Inc Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed
AR051596A1 (es) 2004-10-26 2007-01-24 Irm Llc Compuestos heterociclicos condensados nitrogenados como inhibidores de la actividad del receptor canabinoide 1; composiciones farmaceuticas que los contienen y su empleo en la preparacion de medicamentos para el tratamiento de trastornos alimentarios
EP1820797A4 (fr) * 2004-12-01 2009-10-28 Banyu Pharma Co Ltd Derive substitue de pyridone
GB0428514D0 (en) 2004-12-31 2005-02-09 Prosidion Ltd Compounds
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
GT200600046A (es) 2005-02-09 2006-09-25 Terapia de combinacion
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
NZ564759A (en) * 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
EP1907383A1 (fr) * 2005-06-30 2008-04-09 Prosidion Limited Agonistes du gpcr
US20090221644A1 (en) 2005-06-30 2009-09-03 Stuart Edward Bradley Gpcr Agonists
KR20080025190A (ko) 2005-06-30 2008-03-19 프로시디온 리미티드 Ｇ-단백질 결합된 수용체 효능제
NZ565898A (en) 2005-09-16 2010-07-30 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
US7579351B2 (en) * 2005-12-09 2009-08-25 Hoffmann-La Roche Inc. Tricyclic amide derivatives
CN101400653A (zh) 2006-02-07 2009-04-01 惠氏公司 11-βHSD1抑制剂
JP2009532453A (ja) 2006-04-06 2009-09-10 プロシディオン・リミテッド ヘテロサイクリックｇｐｃｒアゴニスト
GB0607196D0 (en) 2006-04-11 2006-05-17 Prosidion Ltd G-protein coupled receptor agonists
DK1971862T3 (da) 2006-04-11 2011-02-14 Arena Pharm Inc Fremgangsmåder til anvendelse af GPR119-receptor til identificering af forbindelser anvendelige til øgning af knoglemasse hos en person
PE20071221A1 (es) 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
GB0610746D0 (en) 2006-06-01 2006-07-12 Prosidion Ltd Method of treatment
TW200811147A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
TW200811140A (en) 2006-07-06 2008-03-01 Arena Pharm Inc Modulators of metabolism and the treatment of disorders related thereto
JP2009543805A (ja) 2006-07-13 2009-12-10 スミスクライン ビーチャム コーポレーション インドリン誘導体及びｇｐｒ１１９作動物質
JP2010501629A (ja) 2006-08-30 2010-01-21 ビオヴィトルム・アクチボラゲット（プブリクト） Ｇｐｒ１１９関連障害を治療するためのピリジン化合物
US20080076750A1 (en) 2006-09-15 2008-03-27 Aslanian Robert G Azetidinone Derivatives and Methods of Use Thereof
JP2010503676A (ja) 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛、糖尿病および脂質代謝の障害の治療
US20080255155A1 (en) 2006-10-18 2008-10-16 Stephane Raeppel Kinase inhibitors and uses thereof
AU2008222812B2 (en) 2007-03-08 2012-03-22 Irm Llc Compounds and compositions as modulators of GPR119 activity
JP5147866B2 (ja) * 2007-03-15 2013-02-20 メルク・シャープ・アンド・ドーム・コーポレーション グルカン合成酵素阻害剤として有用であるピリダジノン誘導体
DK2137162T3 (en) 2007-03-15 2018-11-26 Novartis Ag Organic compounds and their applications
WO2008126886A1 (fr) * 2007-04-12 2008-10-23 Taisho Pharmaceutical Co., Ltd. Dérivé d'indole ou d'indoline
RU2443699C2 (ru) 2007-09-20 2012-02-27 Айрм Ллк Соединения и композиции в качестве модуляторов активности gpr119
EP2108960A1 (fr) 2008-04-07 2009-10-14 Arena Pharmaceuticals, Inc. Procédés d'utilisation d'un récepteur couplé à protéine G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement des conditions modulées de secrétagogues BY (PYY) et composés utiles dans le traitement des conditions par PYY
JP5378825B2 (ja) 2009-02-17 2013-12-25 出光興産株式会社 Ｇｐｒ１１９アゴニスト
AR072725A1 (es) 2009-07-08 2010-09-15 Merck Sharp & Dohme Compuestos de ciclopropilo sustituido composiciones que contienen tales compuestos y metodos de tratamiento

Also Published As

Publication number Publication date
TWI368618B (en) 2012-07-21
RU2443699C2 (ru) 2012-02-27
AU2008302570A1 (en) 2009-03-26
US20120196844A1 (en) 2012-08-02
CR11292A (es) 2010-03-22
CN101801954B (zh) 2013-10-09
RU2010115260A (ru) 2011-10-27
CA2697551A1 (fr) 2009-03-26
PE20090708A1 (es) 2009-07-15
TW200914448A (en) 2009-04-01
CN101801954A (zh) 2010-08-11
WO2009038974A1 (fr) 2009-03-26
EP2197873A1 (fr) 2010-06-23
ECSP10010042A (es) 2010-04-30
AU2008302570B2 (en) 2012-05-31
AR068496A1 (es) 2009-11-18
KR20100055536A (ko) 2010-05-26
JP5465177B2 (ja) 2014-04-09
CO6270362A2 (es) 2011-04-20
JP2010540441A (ja) 2010-12-24
US8153635B2 (en) 2012-04-10
US8258156B2 (en) 2012-09-04
MA31764B1 (fr) 2010-10-01
CL2008002787A1 (es) 2009-05-15
ES2499018T3 (es) 2014-09-26
US20090270409A1 (en) 2009-10-29
NZ583495A (en) 2011-11-25
MX2010003117A (es) 2010-04-01
CA2697551C (fr) 2013-03-12
US20110224185A1 (en) 2011-09-15
EP2197873B1 (fr) 2014-07-16
BRPI0817211A2 (pt) 2017-05-16

Similar Documents

Publication Publication Date Title
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
PL2134704T3 (pl) Związki i kompozycje pełniące rolę modulatorów aktywności GPR119
PH12020550450A1 (en) Certain chemical entities, compositions and methods
EA200901032A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2012004078A (es) Compuestos y composiciones como moduladores de la actividad de gpr119.
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
EA201001332A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
IN2012DN02469A (fr)
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201001330A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
MY172151A (en) Certain chemical entities, compositions and methods
MX2009006339A (es) Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
TW200801021A (en) Imidazolothiazole compounds for the treatment of disease
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
TW200745109A (en) Pyrrolo-pyridine kinase modulators
IN2012DN01961A (fr)
ECSP088852A (es) Azolopirimidinas como inhibidores de la actividad canabinoidea 1
UA103930C2 (ru) Соединения и композиция для лечения паразитарных болезней
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
WO2011014520A3 (fr) Composés et compositions pouvant servir de modulateurs de l&#39;activité du gpr119
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
TW200603791A (en) Compounds and compositions as cathepsin S inhibitors
UA97289C2 (ru) Соединения и их композиция как модуляторы gpr119 активности